As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community. Innovation represents one of the strongest pillars of the company with more than 50 in-house scientists and a unique network of talented and renowned medical doctors contributing to Regen Lab’s Research & Development.
Over nearly 15 years, this innovation has been secured by building substantial patent & trademarks portfolios. Intellectual Property Rights (IPRs) therefore represent core assets of the company protecting its unique products and forging Regen Lab’s renowned brand names.
The patent portfolio can be divided into two core technologies:
1-PRP/BMC gel devices, methods and uses thereof, alone or in combination with cell extracts and associated key technologies like Autologous Thrombin Serum (ATS) and PRP Cell Culture.
Associated trademarks are REGENLAB®, REGENKIT®, REGENACR®, PRP®, A-PRP®, REGENCELL®, REGENPLASMA®, REGEN PRP®, REGEN®, REGEN EXTRACELL®, THT®, cellularmask®, CUTECELL®, REGENVET®, A-CPKIT® which are registered trademarks of REGEN LAB SA in Europe, United States and other countries.
2-Hyaluronic acid alone, cross-linked or not, or in combination with PRP/BMC leading to the unique “all in one” Cellular Matrix products combining in a synergetic manner the advantageous properties of PRP and HA, but also preparation in two separate devices.
Associated trademarks are REGENLAB®, REGENKIT®, CELLULAR MATRIX® fig., SKINVISC®, ARTHROVISC®, REGENMATRIX®, REGEN®, PRP® and A-PRP® which are registered trademarks of REGEN LAB in Europe, United States and other countries.
V2023.1 | January 26, 2023 | ||
TECHNOLOGY |
PRODUCTS/TRADEMARKS | PATENTS | COMPETITORS |
[not limited to] |
[not limited to] |
||
A-PRP & BMC, glue and membranes Combination with Cell Extracts, Cell Culture |
RegenACR®, RegenKit® Surgery, RegenKit® BCT, A-CP Kit®, Regen Fibrin Polymer, RegenKit® Extracell – Regen Extracell®, Regencell®, THT®, Cutecell®, A-PRP®, REGENPRP®, REGEN®, PRP®, Regenvet® |
Granted US11241458, US11110128, US11096966, US10881691, US10092598, US10080770, US10064894, US8529957, US9833478, US10052349, US11241458, US11389482, EP3395383B, EP3111974B1, CH696752, HK1231793 | FTO restricted with gel technology. |
Pending U.S. Serial 17/837,825, EP22200374.1, WO2008/023026, WO2011/110948, WO2016/083549, WO2019/155391 |
|||
ATS alone or combination with A-PRP for biological glues and membranes |
RegenKit® ATS | Granted US10226516, EP3403659B, AU2013203115B, JP6359495, JP6588499, CA2915649, IL252122, KR10-2136314, IN330984, HK1179507 |
FTO restricted with gel technology. |
A-CP ATS Kit |
Pending WO2011/110948, CN105998067, CN202211204780.2, RU2018133055/20 |
||
Combination therapy: A-PRP & Hyaluronic Acid |
Cellular Matrix® fig. kits (linear HA)
RegenMatrix® (X-linked HA) PRPVISC® |
Granted US10272139, US8945537, US9517255, US10052349, EP2544697B1, EP3184114B, EP2771241B, CA2789533C, JP6076091, JP6321119, JP6892485, AU2011225828B, IL221133, RU2614722, RU2667964, KR20130067247, IN330984, HK1179507
US11077241, EP3223875B, AU20150352458B, EA035982B, MA40376B, IL252536, MX382517, UA123822, KR102362722B1, BR112017010837, BH1857-20220915 |
None for sale. FTO restricted with gel technology. FTO restricted with HA in centrifugation tube. |
Pending WO2011/110948, WO2013/061309, WO2019/155391 |
|||
Cellular Wound |
Granted IL284309, AU2021201102B2 |
||
Hyaluronic Acid only | Arthrovisc®, Skinvisc® | Pending WO2019/155391, WO2013/061309 |
From third-parties only. |
VIRAL INFECTIONS / COVID-19 |
Regenplasma®/A-CP | Pending WO2021/198312, CA3170584, AU2021249444, EP4114526, US serial no. 17/916,507 |
None for sale. |
ALBUMIN BASED BIORESORBABLE CROSS-LINKED HYDROGEL | R&D | Granted EP1543846B1 |
None for sale. |
Now is the time to change your patient’s life. Browse ressources and
get connected to treatment that is right for them.
Our Regional offices are
located in